|
Patient
|
Age at start of P (y)
|
Stage at diagn-osis
|
Prior treatment before KI
|
PD-L1 status
|
KI
|
Time on KI alone (m)
|
Time on KI + P (m)
|
Change in target lesions and BOR on KI + P
|
PFS On KI + P (m)
|
OS from KI (m)
|
OS from KI+P (m)
|
Alive (A)/Deceased (D)
|
|---|
|
1
|
56
|
IVC
|
BC, CXRT
|
5%
|
DT
|
4.3
|
3.1
|
32% PD
|
0.7
|
7.4
|
3.1
|
D
|
|
2
|
68
|
IVC
|
BC
|
30%
|
DT
|
9.6
|
3.8
|
21% PD
|
1.5
|
13.4
|
3.8
|
D
|
|
3
|
57
|
IVB
|
Sg, CXRT
|
80%
|
L
|
1.9
|
6.9
|
19% PD
|
1.5
|
8.9
|
6.9
|
D
|
|
4
|
58
|
IVC
|
Sg, CXRT
|
5%
|
DT
|
26.2
|
13.9
|
−7% SD
|
0.6
|
40.1
|
13.9
|
A
|
|
5
|
60
|
IVC
|
BC
|
50%
|
L
|
5.5
|
15.8
|
−8% SD
|
12.8
|
21.4
|
15.8
|
A
|
|
6
|
47
|
IVB
|
Sg, CXRT
|
60%
|
DT
|
2.4
|
3
|
−14% SD
|
3
|
5.4
|
3
|
D
|
|
7
|
69
|
IVC
|
CXRT
|
n/A
|
DT
|
2
|
4.1
|
−19% SD
|
3.1
|
6.2
|
4.1
|
D
|
|
8
|
60
|
IVC
|
SC, BC
|
> 95%
|
DT
|
1.2
|
6.2
|
−35% PR
|
6.2
|
7.4
|
6.2
|
A
|
|
9
|
84
|
IVC
|
Sg-Lobectomy
|
> 10%
|
L
|
2.1
|
8.3
|
−45% PR
|
8.3
|
10.4
|
8.3
|
D
|
|
10
|
57
|
IVC
|
SC, XRT
|
n/A
|
L
|
2.4
|
16.1
|
−47% PR
|
13.1
|
18.5
|
16.1
|
A
|
|
11
|
73
|
IVC
|
Sg, RAI
|
20%
|
T
|
3.7
|
4.9
|
−48% PR
|
2.6
|
6.7
|
4.9
|
A
|
|
12
|
76
|
IVB
|
Sg, RAI
|
> 90%
|
L
|
1.5
|
5
|
−69% PR
|
5
|
5.8
|
5
|
D
|
- Sg Surgery, CXRT Chemoradiation, BC Bridging chemotherapy with paclitaxel with or without carboplatin while awaiting KI, SC Systemic cytotoxic chemotherapy, XRT external beam radiation, RAI radioactive iodine, DT dabrafenib+trametinib, L lenvatinib, T trametinib alone, w weeks, m months, y years, KI kinase inhibitor, BOR best overall response, PFS progression-free survival, OS overall survival, PD progressive disease, SD stable disease, PR, partial response
